rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: A comparison of two treatment regimens and placebo

Tubercle and Lung Disease

Volumn 78, Issue 3-4, 1997, Pages 195-203

  Johnson, B J ^a   Bekker, L G ^b   Rickman, R ^c   Brown, S ^d   Lesser, M ^d   Ress, S ^b   Willcox, P ^b   Steyn, L ^b   Kaplan, G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CLOFAZIMINE; ETHAMBUTOL; ETHIONAMIDE; INTERLEUKIN 2 RECEPTOR; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; RECOMBINANT INTERLEUKIN 2; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE;

ADULT; ARTICLE; BACTERIAL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOSTIMULATION; INTRADERMAL DRUG ADMINISTRATION; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SPUTUM CULTURE; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0031398044     PISSN: 09628479     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8479(97)90026-5     Document Type: Article

References (14)

1. Cole S T. Drug resistance in Mycobacterium tuberculosis. Eur Resp J 1995; 20: 701s-713s.
2. Park M M, Davis A L, Schluger N W, Cohen H, Rom W N. Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-324.
3. Smith K A. Interleukin-2. Ann Rev Immunol 1984; 2: 319-333.
4. Kaplan G, Britton W J, Hancock G E et al. The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. J Exp Med 1991; 73: 993-1006.
5. Teppler H, Kaplan G, Smith K A, Montana A L, Meyn P, Cohn Z A. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J Exp Med 1993; 177: 483-492.
6. Jeevan A, Asherson G L. Recombinant interleukin-2 limits the replication of Mycobacterium lepraemurium and Mycobacterium bovis BCG in mice. Lymphokine Research 1988; 7: 129-140.
7. Johnson B J, Ress S R, Willcox P et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines and Molecular Therapy 1995; 1: 185-196.
8. Deehan D J, Heys S D, Simpson W, Broom J, McMillan D N, Eremin O. Modulation of the cytokine and acute-phase response to major surgery by recombinant interleukin-2. Br J Surg 1995; 82: 86-90.
9. Mangge H, Kenzian H, Gallistl S et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional flammation parameters and clinical subtypes. Arthritis and Rheumatism 1995; 38: 211-220.
10. Deehan D J, Heys S D, Simpson W G, Broom J, Franks C, Eremin O. In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses. Br J Cancer 1994; 69: 1130-1135.
11. Gooding R, Riches P, Dadian G, Moore J, Gore M. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Cancer 1995; 72: 452-455.
12. bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol 1997; 27: 354-360.
13. Davey R T Jr, Chaitt D G, Piscitelli S C et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997; 175: 781-789.
14. Jacobson E L, Pilaro F, Smith K A. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996; 93: 10405-10410.